Locations:
SearchAdvertisement
Yet 21.4% of tested individuals had Lp(a) elevation
Small interfering RNA lowered lipoprotein(a) by 94% during six-month follow-up after a single dose
Phase 2 trial of zerlasiran yields first demonstration of longer effect with each dose of an siRNA
Resourceful approaches to the care of patients with microvascular disease and elevated Lp(a)
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
It's time to increase testing for this major cardiovascular risk factor in advance of new therapies
Undetectable levels achieved for nearly nine months in phase 1 trial
Targeted mRNA blocking could be first effective approach specific to this cardiovascular risk factor
New phase 2 data boost hopes for phase 3 Lp(a) HORIZON trial
Cholesterol guideline, vitamin D, REDUCE-IT and lipoprotein(a)
Advertisement
Advertisement